<DOC>
	<DOCNO>NCT01464437</DOCNO>
	<brief_summary>This phase 2a , multicenter , randomize , double-blind , placebo-controlled , parallel group , fix dose study . AMG 151 evaluate subject type 2 diabetes treat metformin least 3 month prior randomization .</brief_summary>
	<brief_title>AMG 151 Amgen Protocol Number 20100761</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age 18 75 year , inclusive Diagnosis type 2 diabetes mellitus HbA1c level 7.5 % 11.0 % , inclusive , screen Fasting Cpeptide level ≥ 0.2 nmol/L screen BMI ≥ 25 &lt; 45 kg/m2 screening Treated metformin monotherapy least 3 month prior randomization ; metformin dose must ≥ 850 mg daily least 2 month immediately prior randomization If subject treat hyperlipidemia hypertension stable medication 30 day randomization Subject provide informed consent . History type 1 diabetes History significant weight gain loss ( &gt; 10 % ) 4 week randomization Use weight loss medication ( counter prescription ) within 60 day randomization Use oral injectable antihyperglycemic medication ( metformin ) within 3 month prior randomization Use chronic and/or continuous insulin administration &gt; 15 day outpatient set achieve maintain glycemic control prior randomization Have 2 emergency room visit hospitalization due poor glucose control past 6 month Have 1 episode severe hypoglycemia within 6 month prior entry study , currently diagnose hypoglycemia unawareness Evidence active infection interfere study Presence clinically significant organ system disease stabilize may interfere study Currently receive immunosuppressive therapy History positive HIV , chronic hepatitis B C , cirrhosis Have symptomatic congestive heart failure history myocardial infarction , unstable angina , decompensated congestive heart failure stroke past 6 month prior screen . History gastric surgery , vagotomy , bowel resection surgical procedure might interfere gastrointestinal motility , pH absorption Any find screen ECG opinion investigator require cardiovascular evaluation Poorly control hypertension define diastolic pressure &gt; 100 mm Hg systolic pressure &gt; 160 mm Hg ( assess two separate occasion screen period ) Malignancy ( resect cutaneous basal cutaneous squamous cell carcinoma , treat situ cervical cancer consider cure ) within 5 year screen visit ( malignancy occur &gt; 5 year ago , subject eligible documentation diseasefree state since treatment ) Use know inhibitor inducer CYP3A4 permit 30 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>diabetes</keyword>
	<keyword>mellitus</keyword>
	<keyword>metformin</keyword>
</DOC>